## 8 Conclusions
Available online: [[https://ascopubs.org/action/doSearch?field1=AllField&text1=Cost+analysis+of+high+vs.+low+activity+iodine-125+seeds+as+monotherapy+for+permanent+prostate+brachytherapy&Ppub=&Fpub=&AfterYear=&BeforeYear=](https://ascopubs.org/action/doSearch?field1=AllField&text1=Cost+analysis+of+high+vs.+low+activity+iodine-125+seeds+as+monotherapy+for+permanent+prostate+brachytherapy&Ppub=&Fpub=&AfterYear=&BeforeYear=)]([https://ascopubs.org/action/doSearch?field1=AllField&text1=Cost+analysis+of+high+vs.+low+activity+iodine-125+seeds+as+monotherapy+for+permanent+prostate+brachytherapy&Ppub=&Fpub=&AfterYear=&BeforeYear=](https://ascopubs.org/action/doSearch?field1=AllField&text1=Cost+analysis+of+high+vs.+low+activity+iodine-125+seeds+as+monotherapy+for+permanent+prostate+brachytherapy&Ppub=&Fpub=&AfterYear=&BeforeYear=)) (accessed on 25 December 2023). * _ANSTO_ (2020)ANSTO. Available online: [[https://www.ansto.gov.au/products/nuclear-medicine/product-list/pricing](https://www.ansto.gov.au/products/nuclear-medicine/product-list/pricing)]([https://www.ansto.gov.au/products/nuclear-medicine/product-list/pricing](https://www.ansto.gov.au/products/nuclear-medicine/product-list/pricing)) (accessed on 25 December 2023). * _National Research Council (2008)_National Research Council. _Radiation Source Use and Replacement: Abbreviated Version;_ The National Academies Press: Washington, DC, USA, 2008. [CrossRef]
* _[PERSON] et al. (2022)_[PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] In-Canal Assay of High Specific Activity \({}^{60}\)Co at the Advanced Test Reactor. _Nucl. Technol._**2022**, _208_, 303-309. [CrossRef]
* _[PERSON] et al. (1964)_[PERSON] Cobalt-60 Production at Savannah River Reactor Technology Section Savannah River Plant. In Proceedings of the American Nuclear Society (ANS) Process Radiation Meeting, Washington, DC, USA, 13 May 1964. DPSPU 64-30-16. * _International Atomic Energy Agency. Setting Up a Radiotherapy Programme: Clinical, Medical Physics, Radiation Protection and Safety Aspects;_ STI/PUB/1296; International Atomic Energy Agency: Vienna, Austria, 2008; ISBN 92-0-101807-X. * _[PERSON] et al. (1987)_[PERSON]; [PERSON] Generator-Produced Yttrium-90 for Radioimmunotherapy. _J. Nucl. Med._**1987**, _28_, 1465-1470. [PubMed]
* _[PERSON] et al. (2010)_[PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] Radiation Safety Issues in Y-90 Microsphere Selective Hepatic Radioembolization Therapy: Possible Radiation Exposure from the Patients. _Nucl. Med. Mol. Imaging_**2010**, _44_, 252-260. [CrossRef] [PubMed]
* _[PERSON] et al. (2020)_[PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. _J. Med. Econ._**2020**, _23_, 593-602. [CrossRef] [PubMed]
* _[PERSON] et al. (2014)_[PERSON]; [PERSON]; [PERSON] (Eds.) _Nuclear Medicine_, 4 th ed. ; Elsevier: Amsterdam, The Netherlands, 2014; ISBN 978-0-323-08299-0. * _[PERSON] et al. (2020)_[PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] Samarium-153 Production using (n,r) Reaction at TRIGA PUSPATI Research Reactor. _AIP Conf. Proc._**2020**, _2295_, 020019. [CrossRef]
* _[PERSON] et al. (2005)_[PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] Analisis coste-efectividad de samario-153 (Quadrame(r) en el tratramiento del dolor en pacientes con cancer de prostatea y metastasis oseas. _Clin. Trans. Oncol._**2005**, \(7\), 198-204. [CrossRef]* [PERSON] (2013) [PERSON] Economic and Clinical Net Benefits from the Use of Samarium Sm-153 Lexidronam Injection in the Treatment of Bone Metastases. _Int. J. Tumor Ther._**2013**, \(2\), 10-17. * [PERSON] (2013) [PERSON]; [PERSON] When Should Radiopharmaceuticals Be Considered for Pain Management?